SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
11 avr. 2024 20h58 HE
|
Schall Law
The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
OCGN INVESTOR NEWS: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – OCGN
11 avr. 2024 19h18 HE
|
The Rosen Law Firm PA
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen,...
OCUGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm
02 avr. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ocugen, Inc. (“Ocugen” or...
SHAREHOLDER ALERT: Ocugen Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
02 avr. 2024 11h06 HE
|
Block & Leviton LLP
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Ocugen, Inc. (NASDAQ: OCGN) for potential securities law violations. Investors who have lost money in their Ocugen,...
Ocugen to Present at Investing in Cures Summit
06 mars 2024 07h30 HE
|
Ocugen
MALVERN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen to Present at Pharma Market Research Conference
31 janv. 2024 08h00 HE
|
Ocugen
MALVERN, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
16 janv. 2024 07h30 HE
|
Ocugen
MALVERN, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
13 déc. 2023 07h30 HE
|
Ocugen
MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
09 nov. 2023 06h30 HE
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed...
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
21 sept. 2023 07h30 HE
|
Ocugen
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...